2023 American Association of Neurology Annual Meeting

BioSensics is thrilled to sponsor, attend, and present at the upcoming 2023 AAN Annual Meeting in Boston, MA (Booth #1092). At the event, we will be giving 5 presentations, in both oral and poster formats, that will highlight our efforts in creating digital measurement tools and biomarkers for various conditions, such as ALS, myasthenia gravis (MG), progressive supranuclear palsy (PSP), multiple system atrophy (MSA), and Alzheimer's. 

On Monday, April 24, Dr. Vaziri will be giving an oral presentation titled "Remote Multimodal Monitoring of Motor Neuron Disease Progression using Wearable Sensors and Digital Assessments".  The study shows that sensor-derived measures of physical activity and upper limb function have significant correlations with both gross motor and upper extremity motor subdomain scores of the ALSFRS-R, respectively. In addition, digital speech biomarkers show moderate to significant correlations with the bulbar and respiratory distress subdomain scores of the ALSFRS-R.

Our team will be presenting a poster titled "Instrumental Activities of Daily Living (IADL) as a Digital Biomarker of Cognitive Decline in Older Adults". This poster will focus on our research, supported by the NIH, involving the development of novel solutions for the early detection of and monitoring of cognitive decline in dementia.

On Tuesday, April 25, Dr. Amanda Guidon from Massachusetts General Hospital will be presenting a poster entitled "BioDigit MG: A Pilot Study Examining a Digital Technology for Quantitative Assessment and Remote Monitoring of Myasthenia Gravis". This study is part of a larger $2.5 million/3-year project supported by the NIH focused on remote monitoring and quantitative assessment of MG.

Furthermore, Dr. Daniel Claassen from Vanderbilt University Medical Center will be presenting a poster titled "Wearable Sensors for Quantitative Motor Assessments in Multiple System Atrophy". The poster is in collaboration with Alterity Therapeutics and focuses on the use of PAMSys in tracking disease progression in MSA. 

On Thursday, April 27, Dr. Anne-Marie Wills from Massachusetts General Hospital will be giving an oral presentation titled "Longitudinal Study of Progressive Supranuclear Palsy (PSP) using Remote At-home Multimodal Digital Assessments and Wearable Devices". During this presentation, Dr. Wills will discuss the use of LEGSys and BioDigit Home in a longitudinal study focused on PSP.

About BioSensics: BioSensics is the leader in developing wearable sensors and digital health technologies for clinical trials and research, remote patient monitoring, and health assessments. Founded in 2007 by three scientists from Harvard, BioSensics has created new paradigms in using wearable sensors in healthcare and revolutionized the medical alert industry by creating technologies that are now used by thousands of older adults.

BioSensics is the only company that offers comprehensive end-to-end solutions and services for the acquisition of digital measures and biomarkers in clinical trials and research. BioSensics designs and validates all elements of their solutions, including wearable sensors, software, and algorithms. Our experienced research team extends complete scientific and technical consultation services, such as study design and protocol development, in addition to statistical analysis. Furthermore, BioSensics clinical operations team provides comprehensive operational and logistics support for clinical trial projects.

BioSensics has received over $50M in research and development program support from the U.S. National Institute of Health (NIH). In 2022, BioSensics was chosen by NIH to create remote measurement technologies for use in clinical trials involving people with rare diseases.